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Abstract: Bowel dysfunction in patients with multiple sclerosis (MS) is highly prevalent. 
Constipation and fecal incontinence can coexist and alternate, impacting on the patient’s quality 
of life and social interactions, as well as burdening the caregivers. The cost for the health care 
providers is also significant, with increased number of hospital admissions, treatment-related 
costs, and hospital appointments. The origin is multifactorial, and includes alteration of neu-
rological pathways, polypharmacy, behavioral elements, and ability to access the toilet. Every 
patient with MS should be sensitively questioned about bowel function, and red flag symptoms 
should prompt adequate investigations. Manipulation of life style factors and establishment 
of a bowel regime should be attempted in the first place, and if this fails, other measures such 
as biofeedback and transanal irrigation should be included. A stoma can improve quality of 
life, and is not necessarily a last-ditch option. Antegrade colonic enemas can also be an effec-
tive option, whilst neuromodulation has not proved its role yet. Effective treatment of bowel 
dysfunction improves quality of life, reduces incidence of urinary tract infection, and reduces 
health care costs.
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Introduction
It is estimated that multiple sclerosis (MS) affects around 2.3 million patients worldwide 
and is the commonest non-traumatic cause of disability in young adults.1 The underlying 
pathological mechanism is autoimmune, causing demyelination within the central nervous 
system, which leads to the formation of plaques in the white matter and dysfunction of 
the neurological pathways affected. Clinically, this results in a multitude of neurological 
symptoms and eventually severe disability. MS is classified according to how the symptoms 
present and progress. The most common type is defined as relapsing-remitting, which 
accounts for up to 80% of cases, whilst progressive disease is classified as either secondary 
or primary progressive. Commonly symptoms fluctuate and/or progress, and eventually 
accumulate in relation to the axonal loss and atrophy within the brain and spinal cord.2 
Disability is commonly quantified with the Expanded Disability Status Scale (EDSS),3 
which correlates well with the degree of spinal cord atrophy.4 The precise etiology for 
this disease process is still unknown, and whilst the quest for a definitive treatment is 
ongoing, in the absence of a cure, improvement in symptoms management is imperative.
We will discuss in this review the pathophysiology of MS-related bowel dysfunc-
tion, reviewing the essential anatomy and physiology of defecation, the psychosocial 
and financial impact, and management strategies.
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Methods
The authors conducted a search on PubMed/MeSH and 
Medline databases, using the terms “multiple sclerosis” 
in combination with “bowel symptoms”, “constipation”, 
“fecal incontinence”, and “neurogenic bowel dysfunction”, 
which was also searched independently. We then perused 
the bibliography to extract any further study including pub-
lished abstracts. Given the paucity of studies, particularly 
on treatment, a systematic review was not possible, and this 
is therefore a narrative review, which includes all studies on 
the pathophysiology of MS-related bowel dysfunction and its 
treatment. With regards to symptom management strategies, 
any recommendation is based on the 2014 Cochrane review 
on the management of neurogenic bowel dysfunction5 (NBD) 
and on expert consensus.6
NBD in patients with MS
NBD is a prevalent condition amongst patients with MS, 
affecting overall between 39% and 73% of sufferers depend-
ing on the population studied. The presence of bowel 
symptoms appears to be correlated to the EDSS and disease 
duration, but not with the type of MS.7–11 Nevertheless, 
patients with low disability and a short illness can have bowel 
symptoms and, in fact, severe constipation has been reported 
as the first presenting symptom of MS.12
The definition of constipation is commonly subject to 
individual perception, and generally refers to infrequent 
bowel action and difficulty in releasing stools. A constel-
lation of symptoms might be present, such as tiredness, 
bloating, and abdominal pain. Whilst it remains a symptom 
and not a diagnosis, constipation is defined by the Rome 
criteria13 (Box 1), which should have been fulfilled for the 
last 3 months, with symptom onset at least 6 months prior 
to diagnosis of functional constipation.14
Fecal incontinence (FI) is the involuntary loss of stools or 
flatus for at least 1 month.15 This can occur without the patient 
being aware of it (passive FI), or it can be accompanied by a 
variable degree of urgency (urge FI). Like for constipation, 
it is clinically very important to qualify accompanying stools 
consistency.
Constipation is present in half of the patients with MS, 
and FI affects about 50% of patients at some point and is 
an ongoing symptom in about 25% of cases.8 Commonly, 
constipation and incontinence are coexistent and alternat-
ing. Considering that FI affects 2% of the population16 and 
constipation 2%–20%,17 it is clear that bowel dysfunction is 
far more prevalent in MS patients than the general population.
Psychosocial and physical impact
Patients with MS ranked bowel problems as the third most 
bothersome symptom after fatigue and issues with  mobility.18 
This is not surprising given the embarrassing nature of bowel 
symptoms, and the need to plan activities of daily living 
around bowel care which will affect a persons’ approach 
to social interactions.19 Consequentially, bowel symptoms 
are considered the primary cause of inability to work, after 
spasticity and incoordination.20 These factors, amongst the 
other associated physical challenges, may lead to significant 
psychological and emotional insult.21
The experience of constipation will vary amongst patients 
with MS and the variables will be factors related to the extent 
of difficulty to evacuate, such as how long does the person 
need to spend on the toilet, if they need perineal or rectal 
stimulation, and if they regularly have problems with impac-
tion requiring manual evacuation. In a survey, it was found 
that a third of MS sufferers spend at least 30 minutes for their 
bowel toileting,19 but in clinical experience it is not uncom-
mon, particularly (but not necessarily) in the most disabled 
patients, that toileting takes most of the day in designated 
days of the week. In fact, some patients might hardly ever 
leave the house because of repeated attempts to open their 
bowels, or for the fear of FI.
It only takes one occurrence of an episode of FI, no matter 
the initial reason, to propagate enough anxiety which may 
lead to isolation and self-imposed restrictions in order to 
avoid the risk of what an individual will see as embarrass-
ment, shame, and humiliation if it were to happen.
Anxiety disorders and depression are mental states that 
become a part of the presenting complaint once NBD starts 
to manifest, and they are improved along with successful 
treatment.22 Although multiple explanations can justify what 
could possibly be a “chicken-or-egg” correlation,23 it goes 
to show a significant psychological component associated 
with bowel dysfunction in MS patients as in the normal 
population.24
Box 1 Rome criteria to define constipation, by the presence of 
two or more of these symptoms in at least 25% of the defecations
•	 Straining during defecation
•	 Hard or lumpy stools
•	 Sensation of incomplete evacuation
•	 Sensation of anorectal blockage or obstruction
•	 Use of manual maneuvers to facilitate evacuation (includes 
digitation to the perineum)
•	 Three or less defecations per week
•	 Rarely has loose stools without the use of laxatives
Note: Data from Drossman.13
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As such, these feelings may also contribute to patients 
presenting late, having persevered, endured, and managed 
the symptoms with gradual adaptation even as symptoms 
have progressed over time. Caregivers may inadvertently 
enable this behavior as they also adapt to the effects of NBD 
in order to be supportive and to avoid causing them distress, 
especially when the caregiver is a family member.18 The care-
givers themselves will be affected by the increased need for 
support, if the patients with MS is losing their independence, 
confidence, and self-esteem as the level of care increases. 
Ultimately, these patients are likely to become socially with-
drawn, including reluctance to go and connect with friends 
or family, take holidays, and may become housebound as 
with each venture there is the need to plan access to toilet-
ing facilities.19,21
Other concurrent symptoms, such as hemorrhoids, 
abdominal pain, fecal impaction, rectal bleeding, rectal pro-
lapse, anal fissure, abdominal bloating, nausea, autonomic 
dysreflexia, and prolonged evacuation, can complicate NBD 
contributing to impaired quality of life25–30 and aggravate the 
physical impact of NBD. Food restrictions, in an attempt to 
avoid incontinence, can lead to weight loss. On the other hand, 
the inability to work can lead to a nutritionally poor diet.
economic impact
The cost of standard bowel care for NBD-related FI is just 
under £10,000 per patient. Symptomatic patients are more 
likely to seek medical attention from the general practitioner, 
medical specialists, and dieticians; they are twice as likely to 
require emergency hospital admission which may be related 
to fecal impaction, megacolon, and volvulus,31 and the esti-
mated cost of a typical hospital admission for constipation 
in a patient with MS is estimated at £1,729.32 Some patients 
will go on to require elective or emergency surgery followed 
by inpatient stay to manage NBD.
Effective treatment of NBD is indeed associated with a 
reduction in need for hospitalization, physician visits, number 
of urinary tract infections, and need for surgery,33 with expected 
cost reductions.34 Patients with severe symptoms might be less 
likely to be employed,20 and although no data exist to quantify 
the societal financial impact, it is likely to be significant.
Mechanism of defecation
Normal bowel function is multifactorial and relies not only 
on the anatomical integrity of the bowel and its innerva-
tion, but also on hormonal factors and adequate nutrition, 
which in turn will affect consistency of intra-luminal 
content.  Furthermore, the ability to access the toilet and a 
 behavioral component are essential in maintaining normal 
bowel function.
Schematically, once the stools have reached the large 
bowel, effective colonic transit will allow manipulation of 
stool consistency, reabsorbing water and secreting mucous 
to form the stools. Mass colonic contractions will deliver 
the stools in the rectum, which acts as a reservoir. Essential 
physiological attributes for effective rectal function are good 
compliance and ability to sense its luminal content. The 
rectoanal inhibitory reflex (RAIR, Figure 1) will ensure that 
rectal content is identified at somatic level and released if 
and when it is perceived to be a socially acceptable time.
The areas of the brain thought to be involved in gut func-
tion include the cingulate cortex, insula, thalamus, somato-
sensory cortex, and prefrontal cortex.35
The extrinsic innervation pathway to the bowel involves 
somatic and visceral sensorial fibers. Somatic afferents are via 
the pudendal nerve which innervates the external anal sphinc-
ter and provides anal sensation. Parasympathetic nerves of 
the sacral plexus S2–S4 are responsible for rectal sensation. 
Proximal colonic innervation is from the vagus nerve for 
the parasympathetic stimulating and sensorial component, 
whilst the thoracic spinal cord (T5–L2) supplies inhibitory 
sympathetic fiber to the colon and rectum. The internal anal 
sphincter has tonic sympathetic activity which helps to main-
tain the resting tone of the anal canal. The voluntary striated 
muscle fibers of the external sphincter are also supplied by 
the pudendal nerve, from the Onuf’s nucleus, via the ventral 
horn of the spinal cord.36
The intrinsic pathway is called the enteric nervous 
system (ENS) which has two components: the myenteric 
plexus, which controls the smooth muscles of the gut, and 
the submucosal plexus, which regulates the secreto-motor 
and sensory components of gut function. The ENS works to 
coordinate peristalsis, secretion, and absorption of luminal 
content within the gut.37
The spinal cord conducts signals from gut to brain and 
vice versa within the dorsal column and spinothalamic 
tracts. The act of defecation is the result of a coordinated 
reflex activity at spinal cord level, which is modulated and 
influenced by the cortex.
The precise neuropathological mechanism underlying 
NBD in MS results is not defined. However, the disease pro-
cess can affect these pathways directly and at multiple levels.
At cortical level, demyelination within the frontal lobe 
may affect one’s voluntary control over defecation.38
The role of the spinal cord in maintaining normal bowel 
function is evident, as NBD is almost invariably present in 
 
D
eg
en
er
at
ive
 N
eu
ro
lo
gi
ca
l a
nd
 N
eu
ro
m
us
cu
la
r D
ise
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
15
1 
on
 1
0-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Degenerative Neurological and Neuromuscular Disease 2018:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
82
Preziosi et al
patients with a spinal cord injury (SCI).39 In patients with MS, 
it has been shown that there are delays in the motor pathways 
to the anal sphincter,40,41 as well as delay in generated evoked 
potentials within the spinal cord.42
Most studies have focused on measuring alterations on 
the end organ, particularly the anorectal unit. Anal sphincter 
has been observed to be weak, and anorectal sensation has 
been shown to be reduced in some patients with bowel symp-
toms.10,11 Whilst these findings are certainly significant, no 
conclusion can be made on the underlying pathophysiology.
Rectal compliance is a measure of the ability of the 
rectum to distend, and its alterations are well documented 
cause of both FI43 and constipation.44 In patients with NBD, 
the tone and function of the smooth muscle of the rectal wall 
can be altered resulting in impaired compliance, as shown in 
patients with a SCI.45 These findings suggest a primary role 
of the spinal cord in maintaining rectal compliance. Crucial 
evidence in demonstrating the role of the spinal cord in 
determining bowel symptoms in patients with MS came from 
a study which showed that rectal compliance was altered in 
a predictable manner, depending on the clinical degree of 
spinal cord disease, and that patients with higher EDSS had a 
rectal compliance similar to that of patient with a supraconal 
SCI. On the contrary, patients with low disability had rectal 
compliance similar to that of normal controls.46,47
Rectal sensation and the RAIR both depend on rectal 
distension and are thus related to rectal compliance. Altera-
tions of these three elements have been studied separately, 
but might in fact act in synergy.44
Pelvic floor dyssynergia occurs when abdominal and 
rectal wall contraction are not coordinated with pelvic floor 
relaxation, resulting in the inability to evacuate the rectum, 
and is commonly observed in patients with functional con-
stipation.48 This phenomenon, also called anismus, has been 
well documented in MS patients.49,50 In non-neurological 
patients, pelvic floor dyssynergia is behavioral in nature. 
The same might apply to MS patients, but it could also be a 
pelvic floor manifestation of spasticity and incoordination, 
and parallel to bladder detrusor dyssynergia.51
Improvement of pelvic floor dyssynergia can normalize 
colonic transit in idiopathic constipation,52 and this goes to 
show how the function of the anorectal unit is clearly inte-
grated with large bowel motility. With regards to the activity 
of the more proximal large bowel, slow colonic transit is a 
Figure 1 Rectoanal inhibitory reflex (RAIR).
Notes: excitation peak: initial increase in the resting pressure is associated with sudden rectal distension. excitation latency: duration from the point of excitation peak back 
to the baseline pressure. Point of maximum relaxation: lowest point of resting pressure secondary to reflex internal anal sphincter relaxation. Recovery time: the duration 
between maximum relaxation and the point at which the resting pressure recovers to two-thirds its baseline value. Total reflex duration: calculated as the duration from 
the point of the excitation peak to the point where two-thirds recovery is observed. Figure reproduced from Thiruppathy K, Roy A, Preziosi G, Pannicker J, emmanuel A. 
Morphological abnormalities of the recto-anal inhibitory reflex reflects symptom pattern in neurogenic bowel. Dig Dis Sci. 2012;57(7):1908–1914. Copyright 2012 Thiruppathy 
et al.47
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feature which has been repeatedly observed. It is possible 
that this is secondary to anismus, but could be secondary to 
unopposed sympathetic inhibitory outflow due to spinal cord 
plaques53,54 or secondary to a dampened gastrocolic reflex.55 
In the same study of colonic function, uncontrolled peristalsis 
was observed in patients with MS and diarrhea.55
A schematic view of how all these alterations can inter-
play to cause NBD is summarized in Figures 2 and 3.
Figure 2 Diagram showing the multifactorial origin of constipation.
Notes: Adapted from Preziosi G. Pathophysiology of Bowel Dysfunction in Multiple Sclerosis and the potential for targeted treatment [Doctoral thesis]. London, UK: University 
College London; 2014. Copyright 2014 Preziosi.85
Abbreviations: FI, fecal incontinence; RAIR, rectoanal inhibitory reflex.
Behavioral
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Anorectal
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Figure 3 Diagram showing the multifactorial origin of fecal incontinence.
Notes: Adapted from Preziosi G. Pathophysiology of Bowel Dysfunction in Multiple Sclerosis and the potential for targeted treatment [Doctoral thesis]. London, UK: University 
College London; 2014. Copyright 2014 Preziosi.85
Abbreviation: RAIR, rectoanal inhibitory reflex.
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Treatment
Symptoms assessments
It is well documented that FI is considered a taboo topic 
by both patients and physicians, as observed in the general 
population.56–58 Furthermore, in patients with MS and their 
caregivers there might be a passive acceptance of these 
symptoms as normal. To compound this, bowel symptoms 
can be perceived to be less relevant within the bigger picture 
of their disease.21 Over the last few years, there has been 
increased awareness of the need to enquire about bowel 
function in patients with MS.59 It is worth remembering that 
bowel symptoms can be present regardless of disease dura-
tion, type, or level of disability.
We have described the potential neuropathological 
mechanisms underlying bowel symptoms, but it should be 
always in the mind of the assessing physician or nurse its 
multifactorial nature and the need for a holistic assessment.
Any “red flag” symptoms, such as the presence of blood 
in the stools, a change in bowel habit with no apparent cause 
(disease relapse, change in lifestyle or medications), or unex-
plained weight loss should prompt endoscopic evaluation 
and/or cross-sectional imaging. Bowel function before MS 
diagnosis needs to be explored, including any history of an 
eating disorder. An assessment of diet and nutritional status 
includes evaluation of fluid intake, which is often restricted 
in order to prevent bladder symptoms.
Coexistent symptoms of foregut dysmotility should 
also be sought, asking for symptoms of early satiety and 
abdominal distension.
Comorbidities should be carefully evaluated, including 
diabetes and a history of obstetric injuries. Given the common 
neurological pathways of pelvic organs, urogenital dysfunc-
tion needs to be adequately assessed. It should also be noted 
that a higher incidence of inflammatory bowel disease is 
observed in patients with MS.60
A detailed drug history could reveal the use of constipat-
ing agents, particularly anti-muscarinic drugs and drugs used 
for spasticity such as baclofen. Polypharmacy in general can 
be a cause of constipation, whilst metformin, statins, and 
antibiotics might be responsible for loose stools.
Patients with MS might have a normal and preserved 
urge to defecate, but this can be reduced or completely lost 
and/or associated with a sudden urgency. In some patients, 
the need to open the bowels can present as abdominal pain 
and occasionally as the worsening of symptoms of spasticity. 
Evaluation of frequency of a bowel action and time spent in 
the toilet are important as well as stool consistency, and the 
Bristol stool chart can be useful. Behavioral aspects need 
questioning, including multiple attempts to empty the bowel 
and toilet awareness, which is a need for the patient who is 
constantly mapping the presence of toilets, for example, on 
the route to work. Patients might complain of difficulty with 
wiping clean, which is a sign of incomplete rectal emptying.
Symptoms of FI, including urgency, are often undisclosed 
and should be sensitively explored.
Bowel symptoms in MS patients cover a spectrum, which 
includes at one end the extreme symptoms of obstinate con-
stipation and at the other of complete passive FI. In many 
patients, both constipation and incontinence can be present, 
and in fact correlated, as reduced rectal sensitivity will not 
provide any awareness of rectal fullness, with subsequent 
sudden onset of urgency resulting in FI.
With regards to physical examination, digital rectal 
examination (DRE) is crucial. It could reveal any complica-
tion of bowel dysfunction, such as hemorrhoids or fissures, 
as well as allowing to assess for the presence of hard stools 
or fecal impaction which are signs not only of constipation 
but is also causative of overflow diarrhea. DRE also allows 
a crude assessment of anal sensation, as well as anal tone 
and squeeze pressure.
Specialist tests are indicated in patients with severe or 
persistent symptoms. They include tests of anorectal physiol-
ogy, which will give an accurate measure of somatovisceral 
anorectal sensation and anal sphincter pressures, colonic 
transit time studies, and endoanal ultrasound assessing integ-
rity of the anal sphincters. MRI proctography is occasionally 
used to evaluate the presence of enteroceles or pelvic floor 
dyssynergia.
Accurate quantification of symptoms includes the use of 
a bowel diary for 2 weeks, which will avoid recollection bias 
and give both the physician and patient a realistic evaluation 
of frequency of symptoms. The NBD questionnaire, designed 
for SCI patients, gives a good evaluation of symptoms and 
impact on quality of life. However, simple questioning on 
the percentage (0%, 25%, 50%, 75%, and 100%) by which 
bowel symptoms are affecting the patient’s life,61 or more 
simply if they are absent, mild, moderate, or severe, will give 
a comparable good assessment of their severity.62
The Wexner Constipation and Incontinence scores give a 
good quantitative assessment and have been employed before 
with MS patients. Other questionnaires, such as the St Marks 
Score, is more useful in a research setting.
Bowel regime
At present, the management of bowel dysfunction in MS 
patients remains unsatisfactory,63 and much of the evidence 
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available on the treatment of NBD comes from studies in 
patients with a SCI, with whom MS patients share many 
similarities.
The establishment of a bowel regime requires a thorough 
understanding of the patient’s symptoms as well as his or her 
need for social interaction, work engagements, and level of 
support available both from caregivers and local institutions. 
Whether treatment has failed or not attempted yet, the aim is 
to develop a routine that works for the patient. The first step 
is to engage the patient and the primary caregiver in a process 
that might require trial and failure, with the understanding that 
any intervention might worsen symptoms and might not have a 
long-lasting effect. In fact, it is of paramount importance that 
both physician and patient are aware that the treatment of bowel 
dysfunction follows the opposite of the rule where “one size 
fits all”. Whilst occasionally success can be quickly and eas-
ily obtained with a laxative or anti-diarrheal prescription, the 
patient and caregivers, as well as the physician or nurse treating 
patients with MS, need to understand that improvement might 
require time, titration of medications, and changes in lifestyle. 
In other words, both health care practitioners and patients need 
to agree on embarking in a journey, and that it unlikely that 
one single visit will successfully address symptoms.
Manipulation of stool consistency if necessary is very 
important and can be achieved by modulating water and fiber 
intake. The balance to strike is between having enough fiber 
to have soft formed stools, preventing incontinence and con-
stipation, and at the same time avoiding bloating, which can 
occur with excessive fiber intake or with the use of laxatives, 
in the presence of pan-gut dysmotility. The presence of the 
latter can be only presumed but not always be established in 
the clinical setting, hence the importance of explaining this 
to the patient, so that fiber intake can be adjusted accordingly 
during the development of a bowel regime.
A cautious use of a constipating agent can often signifi-
cantly improve FI.59 Depending on patient’s engagement and 
ability, the titration of loperamide syrup can allow to quan-
tify exactly the dose required to improve stools consistency 
without causing constipation. The patient could then move 
to the tablet form, if more convenient, at the established 
dose. Anti-diarrheal agents should be available to be used as 
required when traveling or for social engagements.
Excessive caffeine, alcohol, or foodstuffs containing 
sorbitol can also cause loose stools.64
Strategies to maximize bowel emptying will prevent fecal 
impaction as well as incontinence and include maximization 
of laxative effect where required.
Additional measures might include abdominal massage, 
using the heel of the palm in a right to left circular motion.65
It should be remembered that addressing constipation 
will often ameliorate symptoms of FI if present, and so we 
will look at overall available treatment modality, rather than 
looking at treatment of a specific symptom.
Laxatives
Scant evidence exists on the use of laxatives, mostly from 
studies of neurological condition or idiopathic bowel symp-
toms; however, clinical experience dictates that a laxative 
regime needs to be tailor made, as many variables affects 
their efficacy. So regardless of the evidence, more than one 
laxative might need to be attempted before satisfactory 
effects are obtained. Therefore, it is important to explain to 
the patient, potential lack of beneficial effect as well as side 
effects, such as bloating or diarrhea, and that any occurrence 
should not be considered as a failure of treatment, but rather 
an important step of the trial and error process. It is also 
important to underline that a positive effect from a laxative 
can be subjective, and could increase frequency of bowel 
action, amelioration of ancillary symptoms, or improved 
feeling of evacuation.
Psyllum is a bulking agent which might work for slow-
transit constipation as shown in patient with Parkinson’s 
disease (PD).66A bulking agent might also work in patients 
who are wheelchair bound.67
The use of the osmotic agent lactulose should be cautious 
and used only in patients with very mild symptoms. In fact, 
given the likely presence of pan-gut dysmotility, it is likely 
to cause or aggravate symptoms of bloating, due to fermenta-
tion and production of methane, as well as being ineffective.
Polyethylene glycol equally acts as osmotic agent but 
does not rely on bacterial fermentation for its activation. The 
advantage is that it can be quite effective, and the dose can 
be adjusted within a wide range according to patient’s need. 
In patients with PD, it has proved to relieve constipation.68
A stimulant laxative such as bisacodyl has been shown 
to be very effective in patients with chronic idiopathic 
constipation.69
In clinical experience, these laxatives can work in MS 
patients when used in a stepwise approach in the order in 
which they have been mentioned.
The use of rectal stimulants or digitation can be employed. 
Bisacodyl suppositories act as rectal stimulants, having a 
very rapid onset of action as shown in patients with a spinal 
cord injury.70
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On average, laxatives take around 8 hours to have an 
effect. Therefore, within a bowel regime, they are taken in 
the evening, so that optimal effect can be achieved in the 
following morning. Efficacy will be maximized by the mass 
contractions, typical of the morning rising, and the gastro-
colic reflex, as a result of breakfast and a hot drink.
However, due to variability in gut transit time, the effects 
can be unpredictable. Both patient and caregiver should 
observe this and implement a regime accordingly.
A combination of different laxatives might be more 
effective, with or without the addition of a rectal suppository.
Prucalopride
Prucalopride is a highly selective 5-HT4 agonist that has been 
shown to be effective in patients with chronic constipation.71 
The most frequently reported adverse events of prucalopride 
were headache, nausea, abdominal pain, and diarrhea, which 
were mainly reported on the first day of treatment. In non-
neurogenic constipation, it increases colonic motility and 
thus improves colonic transit time, and can be considered 
as second-line treatment for constipation in patients with 
MS. Medaer et al conducted a small study with patients 
having treatment for 4 weeks and reported that patients had 
improvement in constipation symptoms; however, a larger 
trial is required to strengthen the evidence as this was a small 
randomized controlled trial (RCT).72
Biofeedback (BF)
Bowel BF, in its more conservative definition, is a technique 
that aims at the modification of bowel function through 
behavioral changes with the aid of an external device. The 
device will allow visualization of a function, for example, 
anal sphincter contraction, and feed it back to the patient who 
can then work on modifying it.73 BF addresses pelvic floor 
dyssynergia, as well as sphincter weakness and the ability to 
identify rectal content (rectal sensitivity), whilst learning to 
resist urge to defecate, and can ameliorate both symptoms 
of constipation and FI. Currently, there is no agreement on 
a standardized technique, and provision of this service is 
very patchy.
Three studies have demonstrated its efficacy in patients 
with MS, not only with regards to symptoms, but also in 
improvement of physiological parameters such as squeeze 
and endurance anal sphincter pressures.22,74,75 This in turn 
suggests that there can be a significant behavioral component 
in MS-related bowel dysfunction. BF can induce measurable 
autonomic changes, which are mediated by the spinal cord, 
and recruitment of residual spinal cord function could be 
responsible for the observed physiological changes.52 This 
would be in accordance with the observation that patients 
with less disability appear to benefit more from BF. Whilst 
no strict criteria can be extrapolated from the literature, BF is 
very unlikely to work in patients who are wheelchair bound 
and have lost completely anorectal function. The latter can 
be proved with test of anorectal physiology in case of uncer-
tainty, but clinical examination should reveal complete loss 
of sensation, lack of sphincter tone, and ability to squeeze 
the anus.
No comparative studies have proved that BF is superior to 
a well-established bowel regime, or any other treatment, but 
in current practice is considered as the next step if maximal 
laxative therapy within a bowel regime has failed.
We are not aware of the long-term effects on bowel symp-
toms; it is likely that disease progression might eventually 
hinder bowel function further. Another consideration is that 
the effects might not be permanent, and, like in cognitive 
behavioral treatment on which BF is based, might be reversed 
if the behavioral changes are not regularly implemented.
In our view, BF is a package of care, and as such includes 
titration, under the guidance of a specialist nurse, use of 
laxatives and constipating agents.
Transanal irrigation (TAi)
TAI is a mechanical means of obtaining bowel opening. The 
device consists of a rubber catheter that is inserted in the 
rectum, with a balloon that is inflated to keep it in place and 
create a seal. Water is then irrigated, and when the catheter 
is removed a bowel action is obtained.
The biggest body of evidence mostly comes from trials 
in patients with a SCI, but it has been proved to be effective 
in patients with MS.76,77 Patients are trained to use the device 
at home and then guided by the trainer regarding adjustments 
to the regime.
TAI has certainly made a big impact on the treatment of 
NBD; in fact, it not only improves symptoms, but also reduces 
the time spent for toileting.77 It has also proved to be a cost-
effective treatment, reducing need for hospital admissions, 
physician’s visits, and occurrence of urinary tract infections 
(UTIs).33 The latter is particularly relevant for MS patients, 
in whom UTIs can cause relapse of symptoms.
Compliance with treatment can be an issue, and patient 
and/or caregiver engagement is essential, in order to imple-
ment the necessary adjustments to obtain a successful 
outcome.
As for BF, the use of constipating and laxative agents 
can be used to optimize a bowel regime. The introduction of 
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a mechanized device might help in improving compliance, 
by having a better control and record of usage of variables 
such as the amount of water irrigated and balloon pressure.
Bowel perforation is a rare occurrence, and TAI should 
be avoided in patients who had previous pelvic surgery.78
Neuromodulation
Sacral neuromodulation (SNM), the stimulation of the S2–S3 
nerve root, can be achieved via the sacral nerve or peripher-
ally via the tibial nerve.
Sacral nerve stimulation (SNS) is a two-stage procedure. 
After a 2-week test period, if a positive effect is recorded 
via a bowel diary, then a permanent SNS is implanted. This 
treatment modality has been employed in a small number 
of patients with an incomplete SCI, and improvement in FI 
ranging between 59% and 92% has been reported.79 Retro-
spectively, a significant improvement in symptoms of FI was 
noticed in patients who had an SNS implanted for bladder 
dysfunction. Effects on constipation are less certain.
Use of SNS in patients with MS is only anecdotal, and, 
learning from the bladder experience, should be reserved 
to selected patients with stable relapsing remitting disease 
who had no relapses for at least 2 years.80 A crucial issue is 
not only the progression of disease and consequent loss of 
efficacy, but also the need for MRI scans which might require 
explantation of the stimulator.
Posterior tibial nerve stimulation has shown promis-
ing results for the treatment of bladder dysfunction in MS 
patient,80 but studies on bowel dysfunction are very much 
needed.
The use of an anal plug could be considered in the pres-
ence of refractory soiling.81
Surgery
Antegrade irrigation with water or osmotic agents, commonly 
known as the antegrade continence enema (ACE) procedure, 
can be performed via a surgical appendicostomy82 or percu-
taneously (percutaneous endoscopic colostomy). It is very 
effective in emptying the bowel, but it has been predominantly 
used in children with idiopathic constipation or NBD due to 
myelomeningocele. Very little but positive data exist in adults, 
and the appendicostomy may stenose with time.83
This technique could be particularly attractive for patients 
with very stubborn symptoms of constipation.
Formation of a colostomy or ileostomy can be a very rea-
sonable option for symptoms of FI, as the procedure reduces 
time spent with bowel care and can provide independence, 
improving quality of life for patients. In fact, patients who 
did have a stoma for NBD stated they wished they had it 
done sooner, but possible complications such as hernias are 
more common in patients with neurological diseases than 
neurologically intact patients.84 Furthermore, whilst incon-
tinence and independence of bowel management are often 
greatly enhanced by stoma formation, impairment of colonic 
transit is not altered by the procedure, so stoma irrigation or 
laxative use may continue to be required. In this regard, some 
surgeons prefer performing a laparoscopic loop ileostomy.
Discussion
NBD is highly prevalent in patients with MS and is certainly 
multifactorial. Both constipation and FI can affect these 
patients, and the impact on their life and overall illness is 
significant. Whilst duration of disease and disability might 
make it more likely to develop NBD, even patients with short 
duration and stable disease, with minor disability, might have 
symptoms. Doctors and nurses dealing with MS patients must 
be aware of it, and assess NBD in every patient with MS, 
and effective treatment can improve anxiety and depression 
and the need of medical interventions.
Constipation may relate to neurological processes that 
affect ability to identify rectal filling, colonic motility, pel-
vic dyssynergia, and reduced ability to expel feces due to 
weakened abdominal wall. Non-neurological factors include 
medications and lifestyle or behavioral choices. FI is caused 
by anorectal hyposensitivity, weakness of the anal sphincter, 
or uncontrolled colonic contractions. Non-MS factors can 
be represented by diabetes and obstetric injuries, as well as 
drugs and lifestyle habits. Anorectal hyposensitivity could 
be considered a common factor to both constipation and 
incontinence, and justify coexistence of these two symptoms.
Involvement of the spinal cord by the disease appears to 
have a central role in the pathophysiology of bowel dysfunc-
tion, and accumulation of disease might eventually lead to 
bowel symptoms. These symptoms can occur in patients 
with preserved mobility and low EDSS, suggesting pin-point 
involvement of areas of the spinal cord  or of alternatively 
localized disease in the supra-spinal area modulating defeca-
tion. However, this is only a speculative thought.
The Cochrane review in 2014 focused on the evidence to 
support the management strategies for individuals with NBD, 
and from 20 RCTs only two were exclusively related to NBD 
in patients with MS. Therefore, the level of evidence was not 
adequate to be able to make any strong recommendations for 
the management of NBD in patients with MS.5 However, no 
intervention has absolute contraindication, and a structured 
approach, employing all the existing armamentarium and the 
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lessons learned particularly with SCI patients, should allow 
the development of a bowel regime and a routine.6
The approach to NBD has been described as a pyramidal 
stepwise approach, where after failing medical treatment, BF, 
TAI, and then surgery should be considered in this sequence. 
But a lack of evidence and clinical experience suggests that a 
Rubik’s cube rather than a pyramid might be a better example 
of how to approach treatment for NBD.
For example, BF might help enhance the effects of TAI, 
by maximizing rectal emptying and reducing some of the 
side effects such as persistent leakage of irrigation fluids. 
Use of laxatives and/or constipating agents might improve 
effects of BF or TAI. SNM could enhance the effects of BF, 
or a patient who had a stoma for FI might benefit from the 
use of laxatives (Figure 4).
Having said that, a stepwise approach is sensible, and 
what will make the difference in outcomes, we think, is 
engaging with the patient and understanding what their 
preferences might be.
As discussed, treatment needs to be tailored, and require 
the patient and caregiver to understand that there might not 
be a “quick fix”, and that rather a package of care might be 
required to be developed over a period of time.
Patient’s choice and availability of treatment also play an 
important role. We have discussed how provision of BF is 
inconsistent, and, for example, young patients, with combined 
constipation and incontinence, might find it very convenient 
to use TAI as a first-line treatment, as TAI will reduce time 
for toileting and give the confidence of an empty rectum.
At present, neuromodulation has very little scope for the 
treatment of NBD, but the development of MRI-friendly SNS 
might open possibility for sizeable studies in patients with 
MS-related NBD. Another attractive SNM modality would 
be transcutaneous nerve stimulation, which would avoid the 
need for weekly clinical attendance for needle stimulation.
The ACE procedure could be a viable option for stub-
born constipation, and formation of a stoma for incontinence 
should not be a last-ditch option.
Disclosure
The authors report no conflicts of interest in this work.
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